Join the members of the Chemotherapy and Biotherapy Special Interest Group for a discussion on chemotherapy-induced nausea and vomiting (CINV). You’ll review its incidence, risk factors, and treatment regimens, with a focus on nursing indications. Speakers will share guidelines from ONS, the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN).

**Content Area:** Clinical Practice  
**Content Level:** Intermediate

**Coordinator:**  
Martha Polovich, PhD, RN, AOCN®  
Clinical Associate Professor  
Georgia State University  
Jonesboro, GA  
marty@polovich.com  
**Full Disclosure:**  
Nothing to Disclose

**Speaker:**  
Kristine Abueg, RN, MSN, OCN®, CBCN®  
Clinical Research Nurse  
Kaiser Permanente, Roseville  
Roseville, CA  
kdeano@hotmail.com  
**Full Disclosure:**  
Nothing to Disclose

**Speaker:**  
Patricia Jakel, RN, MN, AOCN®  
Advance Practice Nurse  
Santa Monica, CA  
pjakel@mednet.ucla.edu  
**Full Disclosure:**  
Merck. Educator

**Speaker:**  
Mikaela Olsen, RN, MS, AOCNS®  
Oncology and Hematology Clinical Nurse Specialist  
Sidney Kimmel CCC at Johns Hopkins  
Baltimore, MD  
**Full Disclosure:**  
Nothing to Disclose

**Speaker:**  
Connie Yabes-Sabolboro, RN, MS, OCN®, AOCNS®  
Va Palo Alto Health Care System  
Palo Alto, CA  
Connie.Yabes-Sabolboro@va.gov  
**Full Disclosure:**  
Nothing to Disclose

**Objectives:**  
At the end of this session, participants will be able to:  
1. Describe the pathophysiology of CINV.  
2. Analyze current CINV treatments.  
3. Compare the current ONS, ASCO, and NCCN guidelines on CINV.

**Content Outline:**  
I. Pathophysiology of CINV  
   A. Review the mechanism of CINV.  
   B. Evaluate risk factors and the level of emetic potential.  
      1. Analyze current treatment for CINV.  
         a. Explain the acute phase treatment.  
         b. Explain treatment in the delayed phase—how long to treat.  
II. Compare the current CINV guidelines.  
   A. ONS  
   B. NCCN and ASCO